Alseres Pharmaceuticals, Inc. (ALSE)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alseres Pharmaceuticals, Inc. (ALSE) with AI Score 45/100 (Weak). Alseres Pharmaceuticals, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for central nervous system disorders. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Alseres Pharmaceuticals, Inc. (ALSE) Healthcare & Pipeline Overview
Alseres Pharmaceuticals, Inc., a biotechnology firm, specializes in central nervous system disorder diagnostics and therapeutics. Its primary focus is Altropane, a molecular imaging agent for Parkinson's and dementia. Operating with a small team, the company navigates the competitive biotech landscape while managing the risks inherent in OTC-listed securities.
Investment Thesis
Investing in Alseres Pharmaceuticals, Inc. presents a speculative opportunity due to its OTC listing and focus on a single lead product candidate, Altropane. The company's success hinges on the clinical and commercial viability of Altropane for diagnosing Parkinson's disease and dementia. With a market capitalization of $0.00B and negative P/E ratio, the company's financial performance is currently challenged, indicated by a profit margin of -198.8%. Key growth catalysts include successful clinical trials and regulatory approvals for Altropane. Ongoing risks include the company's limited resources, reliance on a single product, and the inherent uncertainties of the biotechnology industry. The company's gross margin of 95.0% suggests potential profitability if Altropane achieves commercial success.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead product candidate Altropane targets a significant unmet need in the diagnosis of Parkinson's disease and dementia.
- Gross margin of 95.0% indicates potential for high profitability upon successful commercialization of Altropane.
- Market capitalization of $0.00B reflects the company's current early stage and speculative nature.
- Negative P/E ratio and profit margin of -198.8% highlight the company's current lack of profitability.
- Beta of 0.21 suggests the stock is less volatile than the overall market.
Competitors & Peers
Strengths
- Proprietary molecular imaging technology.
- Focus on a specific niche in neurological disorders.
- Potential for high gross margins.
- Dedicated leadership with relevant experience.
Weaknesses
- Limited financial resources.
- Reliance on a single product candidate.
- Small team size.
- OTC listing indicates higher risk.
Catalysts
- Upcoming: Data readout from ongoing clinical trials of Altropane.
- Upcoming: Potential regulatory submission for Altropane.
- Ongoing: Partnership discussions with larger pharmaceutical companies.
- Ongoing: Research and development efforts for new diagnostic and therapeutic products.
Risks
- Potential: Clinical trial failures for Altropane.
- Potential: Regulatory rejection of Altropane.
- Ongoing: Limited financial resources.
- Ongoing: Competition from larger pharmaceutical companies.
- Potential: Patent expiration.
Growth Opportunities
- Successful clinical trials for Altropane: Positive results from clinical trials would validate Altropane's efficacy and safety, potentially leading to regulatory approval and commercialization. The market for Parkinson's disease and dementia diagnostics is substantial, with an aging global population driving demand. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- Regulatory approval for Altropane: Securing regulatory approval from agencies like the FDA would allow Alseres to market and sell Altropane, generating revenue and establishing a market presence. The regulatory pathway is complex and can take several years. Timeline: 2-3 years post successful clinical trials.
- Partnerships with larger pharmaceutical companies: Collaborating with larger pharmaceutical companies could provide Alseres with funding, expertise, and access to established distribution networks. Partnerships can accelerate development and commercialization efforts. Timeline: Ongoing discussions with potential partners.
- Expansion of Altropane's applications: Exploring additional applications for Altropane beyond Parkinson's disease and dementia could broaden its market potential. This could involve investigating its use in diagnosing other neurological disorders. Timeline: 3-5 years, contingent on initial success.
- Development of new diagnostic and therapeutic products: Expanding the product pipeline with new diagnostic and therapeutic candidates could diversify Alseres' revenue streams and reduce its reliance on Altropane. This requires significant investment in research and development. Timeline: Long-term, 5+ years.
Opportunities
- Successful clinical trials and regulatory approval for Altropane.
- Partnerships with larger pharmaceutical companies.
- Expansion of Altropane's applications.
- Development of new diagnostic and therapeutic products.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Patent expiration.
Competitive Advantages
- Proprietary molecular imaging technology for neurological disorders.
- Patent protection for Altropane and related technologies.
- First-mover advantage in specific diagnostic applications.
- Specialized expertise in central nervous system disorders.
About ALSE
Founded in 1972 and based in Auburndale, Massachusetts, Alseres Pharmaceuticals, Inc., formerly known as Boston Life Sciences, Inc., is a biotechnology company concentrating on the development of diagnostic and therapeutic products for disorders of the central nervous system. The company's lead product candidate is Altropane, a molecular imaging agent designed to aid in the diagnosis of Parkinson's disease and dementia. Altropane represents a significant focus for Alseres, aiming to provide a more effective diagnostic tool for these debilitating conditions. The company operates with a small team of three employees, led by Peter G. Savas. Alseres Pharmaceuticals navigates the complexities of the biotechnology industry, focusing its efforts on a specific niche within neurological disorders. The company's evolution reflects a commitment to addressing unmet needs in the diagnosis and potential treatment of central nervous system diseases.
What They Do
- Develop diagnostic products for central nervous system disorders.
- Focus on molecular imaging agents.
- Target Parkinson's disease and dementia.
- Conduct clinical trials to evaluate product efficacy.
- Seek regulatory approval for their products.
- Potentially partner with larger pharmaceutical companies for commercialization.
Business Model
- Develop and commercialize diagnostic products for neurological disorders.
- Generate revenue through sales of diagnostic agents like Altropane.
- Potentially license or partner with other companies for product distribution.
- Seek funding through equity offerings and partnerships.
Industry Context
Alseres Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by high risk and high reward. The company focuses on developing diagnostic tools for central nervous system disorders, a market driven by an aging population and increasing prevalence of conditions like Parkinson's disease and dementia. The competitive landscape includes larger pharmaceutical companies and specialized biotech firms, such as ACHKF, AGFAF, AQQRF, ELVAY, and FLURF, all vying for market share in neurological disease diagnostics and therapeutics. The biotechnology industry is subject to stringent regulatory requirements and lengthy clinical trial processes, adding to the inherent risks.
Key Customers
- Hospitals and clinics specializing in neurology.
- Physicians diagnosing and treating Parkinson's disease and dementia.
- Research institutions conducting studies on neurological disorders.
Financials
Chart & Info
Alseres Pharmaceuticals, Inc. (ALSE) stock price: Price data unavailable
Latest News
No recent news available for ALSE.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALSE.
Price Targets
Wall Street price target analysis for ALSE.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALSE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Peter G. Savas
CEO
Peter G. Savas serves as the CEO of Alseres Pharmaceuticals, Inc., leading a small team of three employees. Information regarding his detailed career history and educational background is not available in the provided data. However, as CEO, he is responsible for the strategic direction and operational management of the company, focusing on the development and commercialization of diagnostic and therapeutic products for central nervous system disorders.
Track Record: Due to the limited information available, it is not possible to assess Peter G. Savas's specific achievements or strategic decisions at Alseres Pharmaceuticals, Inc. His track record is currently unknown, and further information would be needed to evaluate his performance and contributions to the company's milestones.
ALSE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Alseres Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing requirements, resulting in higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements, if available.
- Research the background and experience of the management team.
- Assess the company's business plan and growth prospects.
- Evaluate the competitive landscape and potential market share.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal issues.
- Longevity of the company's operations (founded in 1972).
- Focus on a specific therapeutic area (central nervous system disorders).
- Development of a lead product candidate (Altropane).
- Presence of a CEO (Peter G. Savas).
- Gross margin of 95.0% suggests potential profitability.
Alseres Pharmaceuticals, Inc. Stock: Key Questions Answered
What does Alseres Pharmaceuticals, Inc. do?
Alseres Pharmaceuticals, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for disorders of the central nervous system. Their primary focus is Altropane, a molecular imaging agent designed to aid in the diagnosis of Parkinson's disease and dementia. The company aims to provide a more effective diagnostic tool for these conditions, addressing a significant unmet need in the healthcare market. Alseres operates with a small team and navigates the complexities of the biotechnology industry, focusing its efforts on a specific niche within neurological disorders.
What do analysts say about ALSE stock?
Due to the company's OTC listing and limited analyst coverage, there is no readily available analyst consensus on ALSE stock. Key valuation metrics such as price targets and ratings are not widely tracked. Investment considerations should focus on the company's potential for successful clinical trials and regulatory approval of Altropane, as well as the inherent risks associated with investing in a small, OTC-listed biotechnology company. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for ALSE?
The main risks for Alseres Pharmaceuticals, Inc. include the potential for clinical trial failures, regulatory hurdles, limited financial resources, and competition from larger pharmaceutical companies. The company's reliance on a single product candidate, Altropane, also poses a significant risk. Additionally, the OTC listing increases the risk of low liquidity, price volatility, and potential for fraud or mismanagement. Investors should carefully consider these risks before investing in ALSE.
What are the key factors to evaluate for ALSE?
Alseres Pharmaceuticals, Inc. (ALSE) currently holds an AI score of 45/100, indicating low score. Key strength: Proprietary molecular imaging technology.. Primary risk to monitor: Potential: Clinical trial failures for Altropane.. This is not financial advice.
How frequently does ALSE data refresh on this page?
ALSE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALSE's recent stock price performance?
Recent price movement in Alseres Pharmaceuticals, Inc. (ALSE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary molecular imaging technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALSE overvalued or undervalued right now?
Determining whether Alseres Pharmaceuticals, Inc. (ALSE) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALSE?
Before investing in Alseres Pharmaceuticals, Inc. (ALSE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and potential for volatility.
- AI analysis pending for ALSE.